PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 34238029-8 2021 On mechanism, metformin treatment remarkably reduced mesothelin (MSLN) expression, downregulated IL-6/STAT3 signaling activity, subsequently resulted in VEGF and TGFbeta1 expression. Metformin 14-23 vascular endothelial growth factor A Homo sapiens 153-157 34238029-10 2021 CONCLUSIONS: Collectively, our findings suggested that metformin exerts anticancer effects by suppressing ovarian cancer cell malignancy, which attributed to MSLN inhibition mediated IL6/STAT3 signaling and VEGF and TGFbeta1 downregulation. Metformin 55-64 vascular endothelial growth factor A Homo sapiens 207-211 35139776-5 2022 By activating farnesoid X receptor (FXR), metformin increases the expression of vascular endothelial growth factor-A (VEGF-A) and endothelial nitric oxide synthase (eNOS), improves the production of nitric oxide (NO) and decreases the production of ROS. Metformin 42-51 vascular endothelial growth factor A Homo sapiens 80-116 35139776-5 2022 By activating farnesoid X receptor (FXR), metformin increases the expression of vascular endothelial growth factor-A (VEGF-A) and endothelial nitric oxide synthase (eNOS), improves the production of nitric oxide (NO) and decreases the production of ROS. Metformin 42-51 vascular endothelial growth factor A Homo sapiens 118-124 35139776-7 2022 Thus, metformin appears to regulate islet microvascular endothelial cell (IMEC) proliferation, apoptosis and oxidative stress by activating the FXR/VEGF-A/eNOS pathway. Metformin 6-15 vascular endothelial growth factor A Homo sapiens 148-154 33081077-6 2020 Metformin decreased the NGF-induced transcriptional activity of MYC and beta-catenin/T-cell factor/lymphoid enhancer-binding factor (TCF-Lef), as well as the expression of c-MYC, survivin and VEGF in EOC cells, while it increased miR-23b and miR-145 levels. Metformin 0-9 vascular endothelial growth factor A Homo sapiens 192-196 33049108-10 2020 Moreover, metformin treatment enhanced the expression of pro-angiogenic/osteogenic growth factors BMP2 and VEGF but reduced the osteoclastogenic factor RANKL/OPG expression in SHEDs. Metformin 10-19 vascular endothelial growth factor A Homo sapiens 107-111 30575815-6 2019 In vitro, glucose, insulin, VEGFA and hypoxia upregulated endothelial FABP4, which was reversed by metformin through mTOR pathway inhibition. Metformin 99-108 vascular endothelial growth factor A Homo sapiens 28-33 31002375-0 2019 [Corrigendum] Metformin suppresses hypoxia-induced migration via the HIF-1alpha/VEGF pathway in gallbladder cancer in vitro and in vivo. Metformin 14-23 vascular endothelial growth factor A Homo sapiens 80-84 32452405-11 2020 DISCUSSION: Low dose combination metformin and sulfasalazine reduced cytotrophoblast sFlt-1 and sENG secretion, increased VEGFalpha expression and reduced TNFalpha induced endothelin-1 expression in primary endothelial cells. Metformin 33-42 vascular endothelial growth factor A Homo sapiens 122-131 31120617-0 2019 RasGRP1 is a target for VEGF to induce angiogenesis and involved in the endothelial-protective effects of metformin under high glucose in HUVECs. Metformin 106-115 vascular endothelial growth factor A Homo sapiens 24-28 31120617-4 2019 Furthermore, we investigate whether RasGRP1-dependent VEGF signaling was downregulated under high glucose conditions mimicking diabetes and required for the endothelial protective action of metformin in human umbilical vein endothelial cells (HUVECs). Metformin 190-199 vascular endothelial growth factor A Homo sapiens 54-58 31120617-8 2019 The expression of VEGF, RasGRP1, and AKT phosphorylation was downregulated in HUVECs exposed to high glucose compared with normal glucose, whereas metformin upregulated the RasGRP1-dependent VEGF signaling and ameliorates the impaired angiogenesis caused by high glucose. Metformin 147-156 vascular endothelial growth factor A Homo sapiens 191-195 30710234-8 2019 Moreover, EGCG and metformin treated cells showed decreased expression levels of VEGF. Metformin 19-28 vascular endothelial growth factor A Homo sapiens 81-85 30372835-13 2018 Compared to the control, Metformin blunted the expression of VEGF subtypes and directed cells to energy status by induction of PRKAA1, PRKAB2, and PRKAG1 genes (p < 0.05). Metformin 25-34 vascular endothelial growth factor A Homo sapiens 61-65 30272364-10 2018 Further experiments demonstrated that metformin inhibited hypoxia-induced migration via HIF-1alpha/VEGF in vitro. Metformin 38-47 vascular endothelial growth factor A Homo sapiens 99-103 30272364-11 2018 In addition, metformin suppressed GBC growth and downregulated the expression of HIF-1alpha and VEGF in a GBC-SD cell xenograft model. Metformin 13-22 vascular endothelial growth factor A Homo sapiens 96-100 30272364-0 2018 Metformin suppresses hypoxia-induced migration via the HIF-1alpha/VEGF pathway in gallbladder cancer in vitro and in vivo. Metformin 0-9 vascular endothelial growth factor A Homo sapiens 66-70 30272364-12 2018 Taken together, these results suggest that HIF-1alpha may contribute to tumor migration via the overexpression of VEGF in GBC, while metformin is able to inhibit tumor migration by targeting the HIF-1alpha/VEGF pathway. Metformin 133-142 vascular endothelial growth factor A Homo sapiens 206-210 28427181-12 2017 This may offer us a new avenue for the treatment of related diseases using clinically used pharmacological AMPK activators like metformin in combination with other strategies to enhance the treatment efficacy or in the case of anti-VEGF resistance. Metformin 128-137 vascular endothelial growth factor A Homo sapiens 232-236 29678660-0 2018 Metformin combined with quercetin synergistically repressed prostate cancer cells via inhibition of VEGF/PI3K/Akt signaling pathway. Metformin 0-9 vascular endothelial growth factor A Homo sapiens 100-104 29678660-5 2018 Our data also indicated that co-treatment of metformin and quercetin strongly inhibited the VEGF/Akt/PI3K pathway. Metformin 45-54 vascular endothelial growth factor A Homo sapiens 92-96 29678660-7 2018 In conclusion, our findings indicate that the combination therapy of metformin and quercetin exerted synergistic antitumor effects in prostate cancers via inhibition of VEGF/Akt/PI3K pathway. Metformin 69-78 vascular endothelial growth factor A Homo sapiens 169-173 29670840-2 2018 Metformin and rapamycin may decrease the expression of VEGF protein and subsequently angiogenesis. Metformin 0-9 vascular endothelial growth factor A Homo sapiens 55-59 29344202-8 2017 The present study demonstrated that expression of p-ERK1/2, VEGF, VEGFR2 and Bcl-2 was downregulated by treatment with increasing concentrations of metformin, whereas expression of Bax and caspase-3 was evidently upregulated. Metformin 148-157 vascular endothelial growth factor A Homo sapiens 60-64 27378194-6 2016 Moreover, metformin decreases the production of insulin, insulin-like growth factor, inflammatory cytokines and vascular endothelial growth factor, and therefore it exerts anti-mitotic, anti-inflammatory and anti-angiogenetic effects. Metformin 10-19 vascular endothelial growth factor A Homo sapiens 112-146 25981877-3 2015 Metformin may harbor a pleiotropic action, (a) decreasing inflammation (via anti COX 2 pathway and other mechanism), (b) decreasing COX 2 and VEGF mediated angiogenesis, (c) increasing negative angiogenic regulation pathway by stimulating SMAD 2/3 expression either directly or via the AMPK pathway and preventing from pulmonary hypertension development and (d) diminushin oxidative stress. Metformin 0-9 vascular endothelial growth factor A Homo sapiens 142-146 26861446-0 2016 Metformin improves the angiogenic potential of human CD34+ cells co-incident with downregulating CXCL10 and TIMP1 gene expression and increasing VEGFA under hyperglycemia and hypoxia within a therapeutic window for myocardial infarction. Metformin 0-9 vascular endothelial growth factor A Homo sapiens 145-150 26861446-9 2016 RESULTS: Metformin increased in vitro angiogenesis under hyperglycemia-hypoxia and augmented the expression of VEGFA. Metformin 9-18 vascular endothelial growth factor A Homo sapiens 111-116 26861446-12 2016 CONCLUSIONS: Metformin has a dual effect by simultaneously increasing VEGFA and reducing CXCL10 and TIMP1 in CD34(+) cells in a model of the diabetic state combined with hypoxia. Metformin 13-22 vascular endothelial growth factor A Homo sapiens 70-75 26305116-9 2016 Metformin can exert an anti-inflammatory effect by direct inhibition of IL-6, TNF-alpha, and VEGF. Metformin 0-9 vascular endothelial growth factor A Homo sapiens 93-97 26625311-0 2015 Suppression of tumor angiogenesis by metformin treatment via a mechanism linked to targeting of HER2/HIF-1alpha/VEGF secretion axis. Metformin 37-46 vascular endothelial growth factor A Homo sapiens 112-116 26625311-7 2015 Furthermore, our results of VEGF-neutralizing and -rescuing tests showed that metformin markedly abrogated HER2 signaling-induced tumor angiogenesis by inhibiting VEGF secretion. Metformin 78-87 vascular endothelial growth factor A Homo sapiens 28-32 26625311-7 2015 Furthermore, our results of VEGF-neutralizing and -rescuing tests showed that metformin markedly abrogated HER2 signaling-induced tumor angiogenesis by inhibiting VEGF secretion. Metformin 78-87 vascular endothelial growth factor A Homo sapiens 163-167 26625311-10 2015 Our data thus provides novel insight into the mechanism underlying the metformin-induced inhibition of tumor angiogenesis and indicates possibilities of HIF-1alpha-VEGF signaling axis in mediating HER2-induced tumor angiogenesis. Metformin 71-80 vascular endothelial growth factor A Homo sapiens 164-168 26260219-10 2015 VEGF expression was decreased and E-cadherin increased in the metformin-treated group when compared with the control group. Metformin 62-71 vascular endothelial growth factor A Homo sapiens 0-4 26260219-13 2015 Metformin treatment may be useful for modulating the metastatic capacity by reducing VEGF expression and blocking epithelial-to-mesenchymal transition. Metformin 0-9 vascular endothelial growth factor A Homo sapiens 85-89 25785990-0 2015 Anti-angiogenic effect of metformin in mouse oxygen-induced retinopathy is mediated by reducing levels of the vascular endothelial growth factor receptor Flk-1. Metformin 26-35 vascular endothelial growth factor A Homo sapiens 110-144 25179820-0 2015 The anti-diabetic drug metformin inhibits vascular endothelial growth factor expression via the mammalian target of rapamycin complex 1/hypoxia-inducible factor-1alpha signaling pathway in ELT-3 cells. Metformin 23-32 vascular endothelial growth factor A Homo sapiens 42-76 23879009-13 2013 Metformin has antiproliferative properties; reduces the VEGF levels, causing a reduction in tumor vasculature; causes an increase in progesterone receptor, which increases the response to hormonal therapy; inhibits the expression of glyoxalase I, mediating resistance to chemotherapy; decreases in the concentration of human telomerase; reduces the activity of Akt and Erk kinases, key regulators of metabolism and progression of tumors and also inhibits the formation of metastases. Metformin 0-9 vascular endothelial growth factor A Homo sapiens 56-60 24011132-13 2013 These effects of metformin are mediated by inhibiting the increased of the vasoactive molecules: VEGF, COX-2 and partially NOS. Metformin 17-26 vascular endothelial growth factor A Homo sapiens 97-101 24419232-5 2014 Gene expression profiling of human umbilical vein endothelial cells revealed a paradoxical modulation of several angiogenesis-associated genes and proteins by metformin, with short-term induction of vascular endothelial growth factor (VEGF), cyclooxygenase 2 and CXC chemokine receptor 4 at the messenger RNA level and downregulation of ADAMTS1. Metformin 159-168 vascular endothelial growth factor A Homo sapiens 199-233 24419232-5 2014 Gene expression profiling of human umbilical vein endothelial cells revealed a paradoxical modulation of several angiogenesis-associated genes and proteins by metformin, with short-term induction of vascular endothelial growth factor (VEGF), cyclooxygenase 2 and CXC chemokine receptor 4 at the messenger RNA level and downregulation of ADAMTS1. Metformin 159-168 vascular endothelial growth factor A Homo sapiens 235-239 24419232-8 2014 Metformin inhibits VEGF-dependent activation of extracellular signal-regulated kinase 1/2, and the inhibition of AMPK activity abrogates this event. Metformin 0-9 vascular endothelial growth factor A Homo sapiens 19-23 23526220-9 2013 Both mechanisms contributed to the ability of metformin to suppress STAT3 activation in cancer cells, which resulted in the decreased secretion of vascular endothelial growth factor by cancer cells. Metformin 46-55 vascular endothelial growth factor A Homo sapiens 147-181 23225247-0 2013 Metformin inhibits advanced glycation end products (AGEs)-induced growth and VEGF expression in MCF-7 breast cancer cells by suppressing AGEs receptor expression via AMP-activated protein kinase. Metformin 0-9 vascular endothelial growth factor A Homo sapiens 77-81 23225247-4 2013 We examined here whether and how metformin could block the AGEs-induced growth and vascular endothelial growth factor (VEGF) expression in MCF-7 breast cancer cells. Metformin 33-42 vascular endothelial growth factor A Homo sapiens 83-117 23225247-4 2013 We examined here whether and how metformin could block the AGEs-induced growth and vascular endothelial growth factor (VEGF) expression in MCF-7 breast cancer cells. Metformin 33-42 vascular endothelial growth factor A Homo sapiens 119-123 23225247-8 2013 Furthermore, metformin at 0.01 mM completely suppressed the AGEs-induced upregulation of RAGE and VEGF mRNA levels in MCF-7 cells. Metformin 13-22 vascular endothelial growth factor A Homo sapiens 98-102 23225247-9 2013 An inhibitor of AMP-activated protein kinase, compound C significantly blocked the growth-inhibitory and RAGE and VEGF suppressing effects of metformin in AGEs-exposed MCF-7 cells. Metformin 142-151 vascular endothelial growth factor A Homo sapiens 114-118 23225247-10 2013 Our present study suggests that metformin could inhibit the AGEs-induced growth and VEGF expression in MCF-7 breast cancer cells by suppressing RAGE gene expression via AMP-activated protein kinase pathway. Metformin 32-41 vascular endothelial growth factor A Homo sapiens 84-88 22576211-0 2012 Metformin accelerates the growth of BRAF V600E-driven melanoma by upregulating VEGF-A. Metformin 0-9 vascular endothelial growth factor A Homo sapiens 79-85 22576211-5 2012 Unexpectedly, however, when VEGF signaling is inhibited, instead of accelerating tumor growth, metformin inhibits tumor growth. Metformin 95-104 vascular endothelial growth factor A Homo sapiens 28-32 23653852-10 2012 Metformin at concentrations of 0.5-3 mM significantly (P<0.001) inhibited VEGF mRNA expression and endothelial cell migration. Metformin 0-9 vascular endothelial growth factor A Homo sapiens 77-81 22469973-5 2012 Real-time PCR was used to investigate the effect of metformin on LH induction of VEGF and slit2 expression. Metformin 52-61 vascular endothelial growth factor A Homo sapiens 81-85 22469973-7 2012 However, metformin inhibited the mTOR signaling pathway and further blocked LH-induced VEGF and slit2 expression. Metformin 9-18 vascular endothelial growth factor A Homo sapiens 87-91 21532889-6 2011 Metformin-induced activation of AMPK/mTOR pathway was accompanied by decreased microvessel density and vascular endothelial growth factor expression. Metformin 0-9 vascular endothelial growth factor A Homo sapiens 103-137 18358555-7 2008 Our results indicated that, metformin addition had beneficial effect on VEGF and PAI-1 levels in obese type 2 diabetic patients under MNT+REP, independent from its" favourable effects on BMI and glycemic control. Metformin 28-37 vascular endothelial growth factor A Homo sapiens 72-76 18256928-5 2009 However, when ERalpha negative MDA-MB-435 cells were treated with metformin, they demonstrated increased expression of vascular endothelial growth factor (VEGF) in an AMPK dependent manner; while the ERalpha positive MCF-7 cells did not. Metformin 66-75 vascular endothelial growth factor A Homo sapiens 119-153 18256928-5 2009 However, when ERalpha negative MDA-MB-435 cells were treated with metformin, they demonstrated increased expression of vascular endothelial growth factor (VEGF) in an AMPK dependent manner; while the ERalpha positive MCF-7 cells did not. Metformin 66-75 vascular endothelial growth factor A Homo sapiens 155-159 18256928-8 2009 The metformin-treated group showed increased VEGF expression, intratumoral microvascular density and reduced necrosis. Metformin 4-13 vascular endothelial growth factor A Homo sapiens 45-49 18358555-0 2008 The effect of metformin treatment on VEGF and PAI-1 levels in obese type 2 diabetic patients. Metformin 14-23 vascular endothelial growth factor A Homo sapiens 37-41 18358555-6 2008 After metformin addition, there was a significant decrement in BMI, waist circumference, fat percentage, fasting and postprandial plasma glucose, hemoglobin A1C, plasminogen activator inhibitor-1 (PAI-1), vascular endothelial growth factor (VEGF) and increment in beta cell reserve values of the patients. Metformin 6-15 vascular endothelial growth factor A Homo sapiens 205-239 18358555-6 2008 After metformin addition, there was a significant decrement in BMI, waist circumference, fat percentage, fasting and postprandial plasma glucose, hemoglobin A1C, plasminogen activator inhibitor-1 (PAI-1), vascular endothelial growth factor (VEGF) and increment in beta cell reserve values of the patients. Metformin 6-15 vascular endothelial growth factor A Homo sapiens 241-245